Pub Date : 2023-12-31DOI: 10.23937/2378-3419/1410182
da Silva Thais Cristina Loyola, Ximenes Érika Gabrielle Pinheiro, da Silva Santos Ythalo Hugo, Araújo Rodrigo Jerônimo, de Macedo Eurides Araújo Bezerra, Araújo-Filho* Irami, de Medeiros Kleyton Santos, Petta Tirzah Braz
{"title":"Epidemiological Study of Penile Cancer in Northeast Brazil","authors":"da Silva Thais Cristina Loyola, Ximenes Érika Gabrielle Pinheiro, da Silva Santos Ythalo Hugo, Araújo Rodrigo Jerônimo, de Macedo Eurides Araújo Bezerra, Araújo-Filho* Irami, de Medeiros Kleyton Santos, Petta Tirzah Braz","doi":"10.23937/2378-3419/1410182","DOIUrl":"https://doi.org/10.23937/2378-3419/1410182","url":null,"abstract":"","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88859561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-06-30DOI: 10.23937/2378-3419/1410179
Gbayisomore Oluwafemi, Klausner Hannah, Phelan Shelley A
One of the main components of Pomegranate Seed Oil is punicic acid, an omega-5 fatty acid that is capable of inhibiting breast and prostate cancer cell proliferation, although the mechanisms of action are not yet known. In order to further understand its potential anti-cancer properties, we investigated the effect of punicic acid on proliferation and cytotoxicity of human MCF-7 breast cancer cells. Cells were treated with punicic acid for up to 72 hours, and cell proliferation, cytotoxicity, and apoptosis were measured. We found that 10 and 50 ug/ml punicic acid significantly reduced viable cell density by 72 hours as measured by MTS assay. Similarly, we found that both concentrations significantly increased cytotoxicity by this time point, as measured by an LDH assay. Cell death was confirmed to be, at least in part, due to apoptosis, as detected by Annexin V and propidium iodide fluorescence.
{"title":"Punicic Acid Inhibits Proliferation and Induces Apoptosis in Human MCF-7 Breast Cancer Cells","authors":"Gbayisomore Oluwafemi, Klausner Hannah, Phelan Shelley A","doi":"10.23937/2378-3419/1410179","DOIUrl":"https://doi.org/10.23937/2378-3419/1410179","url":null,"abstract":"One of the main components of Pomegranate Seed Oil is punicic acid, an omega-5 fatty acid that is capable of inhibiting breast and prostate cancer cell proliferation, although the mechanisms of action are not yet known. In order to further understand its potential anti-cancer properties, we investigated the effect of punicic acid on proliferation and cytotoxicity of human MCF-7 breast cancer cells. Cells were treated with punicic acid for up to 72 hours, and cell proliferation, cytotoxicity, and apoptosis were measured. We found that 10 and 50 ug/ml punicic acid significantly reduced viable cell density by 72 hours as measured by MTS assay. Similarly, we found that both concentrations significantly increased cytotoxicity by this time point, as measured by an LDH assay. Cell death was confirmed to be, at least in part, due to apoptosis, as detected by Annexin V and propidium iodide fluorescence.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"2 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"80489569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.23937/2378-3419/1410181
Sulieman Jenan Adnan, Y. Youssef, I. Mostafa
Aim: The aim of the present study is to evaluate the alterations and clinical significance of plasma lipid profiles in untreated head and neck malignancies. Methods: The present case-control study comprises of newly diagnosed and histologically confirmed, 50 head and neck cancer cases between 2021-2022 in the Department of Otorhinolaryngology and Head and Neck Surgery, Tishreen University Hospital, Lattakia, with 25 healthy controls. Fasting blood samples were collected and the lipid profile studied and compared between groups in terms of mean and standard deviation. Results: The mean difference in the levels of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglyceride (TGL) between the case group and control group was significant in our study, that is, these lipid parameters were significantly lower in the case group than that of the control group.
{"title":"Alterations of Serum Lipids Profiles in Patients with Head and Neck Cancers","authors":"Sulieman Jenan Adnan, Y. Youssef, I. Mostafa","doi":"10.23937/2378-3419/1410181","DOIUrl":"https://doi.org/10.23937/2378-3419/1410181","url":null,"abstract":"Aim: The aim of the present study is to evaluate the alterations and clinical significance of plasma lipid profiles in untreated head and neck malignancies. Methods: The present case-control study comprises of newly diagnosed and histologically confirmed, 50 head and neck cancer cases between 2021-2022 in the Department of Otorhinolaryngology and Head and Neck Surgery, Tishreen University Hospital, Lattakia, with 25 healthy controls. Fasting blood samples were collected and the lipid profile studied and compared between groups in terms of mean and standard deviation. Results: The mean difference in the levels of total cholesterol (TC), high-density lipoprotein (HDL), low-density lipoprotein (LDL), very-low-density lipoprotein (VLDL), and triglyceride (TGL) between the case group and control group was significant in our study, that is, these lipid parameters were significantly lower in the case group than that of the control group.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79325152","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-01-01DOI: 10.23937/2378-3419/1410184
Bell Jennifer A, Gettleman Brandon S, Christ Alexander B, Vonck Caroline E, Menendez Lawrence R
{"title":"Intercalary Endoprosthetic Reconstruction for Long Bone Defects of the Lower Extremity","authors":"Bell Jennifer A, Gettleman Brandon S, Christ Alexander B, Vonck Caroline E, Menendez Lawrence R","doi":"10.23937/2378-3419/1410184","DOIUrl":"https://doi.org/10.23937/2378-3419/1410184","url":null,"abstract":"","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"22 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"83092019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2378-3419/1410177
Trivedi Purva, P. Mahesh, Dhotre Sanjay, G. Hansa
{"title":"Colorectal Cancer Screening: Ratios from Hemogram to the Rescue","authors":"Trivedi Purva, P. Mahesh, Dhotre Sanjay, G. Hansa","doi":"10.23937/2378-3419/1410177","DOIUrl":"https://doi.org/10.23937/2378-3419/1410177","url":null,"abstract":"","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"307 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77423992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2378-3419/1410176
Jain Bhushan, Pakalapati Akhila
Treatment paradigms against cancer have continuously evolved over the years. Having said that, with its prevalence of more than 2 million cases each year, breast cancer represents an urgent global priority [1]. Breast carcinomas accounted for 11.6 % of cancer cases and were the cause of mortality in as many as 6.6 % of women in the world in 2018 [2 ]. Toxicity and chemoresistance are significant hurdles in conventional chemotherapy and to avoid these issues, a new approach to drug administration, Metronomic Chemotherapy (MC) has emerged [3]. Metronomic chemotherapy involves treatment at regular, close intervals without prolonged breaks at doses considerably less than the Maximum-Tolerated Dose (MTD) [4]. Recently, MC is being used to intensify adjuvant chemotherapy as well as maintenance therapy for high-risk patients in the adjuvant settings [5
{"title":"The Role of Adjuvant Metronomic Chemotherapy in Increasing Overall Response Rate in Patients with Breast Cancer","authors":"Jain Bhushan, Pakalapati Akhila","doi":"10.23937/2378-3419/1410176","DOIUrl":"https://doi.org/10.23937/2378-3419/1410176","url":null,"abstract":"Treatment paradigms against cancer have continuously evolved over the years. Having said that, with its prevalence of more than 2 million cases each year, breast cancer represents an urgent global priority [1]. Breast carcinomas accounted for 11.6 % of cancer cases and were the cause of mortality in as many as 6.6 % of women in the world in 2018 [2 ]. Toxicity and chemoresistance are significant hurdles in conventional chemotherapy and to avoid these issues, a new approach to drug administration, Metronomic Chemotherapy (MC) has emerged [3]. Metronomic chemotherapy involves treatment at regular, close intervals without prolonged breaks at doses considerably less than the Maximum-Tolerated Dose (MTD) [4]. Recently, MC is being used to intensify adjuvant chemotherapy as well as maintenance therapy for high-risk patients in the adjuvant settings [5","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"65 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"78195916","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2378-3419/1410171
Gunasekaran Gobi Hariyanayagam, Sabri Wan Mohd Akmal Bin Wan, Gunasekaran Shargunan Selvanthan, Gunasekaran Sera Selvanthansundram, Selvarajoo Kavisha
Chemotherapy schedule has been reported to increase the risk of suboptimal outcomes among cancer patients receiving chemotherapy with variying outcome between treatment modality. This study investigates the Overall Survival (OS) and Hazard of Death (HR) of breast cancer patients with chemotherapy schedule modification stratified against adjuvant (ACT) and neoadjuvant (NACT) treatment modalities. The data required for this study was extracted from hospital based registry. Those patients included in the study were adult female patients receiving chemotherapy between 2013 and 2017 and completed all six chemotherapy cycles. Patients who completed all cycle with a cumulative length of delay < 7 days was categorized as 'no schedule modification' and patients who completed all cycle with the cumulative length of delay ≥ 7 days were categorized as 'with schedule modification'. The Kaplan-Meier estimator was used to estimate survival curves for each covariate and the log rank test was used to evaluate the differences in survival times for each category. Among 124 patients included in the study,93 patients were censoredand 31 events was observed, providing an OS of 75.0% with a mean survival of 54.09 months (95% CI 49.36-58.83). There was significantly higher survival (p < 0.001) in ACT treatment (83.9%) and higher mortality in NACT treatment modalities (51.6%). Among ACT treatment modality, those with no schedule modification had a significant proportion of patients surviving(p = 0.04) compared to patients with schedule modification . The OS was significantly different between age (p = 0.013), stage (p = 0.022) and chemotherapy (p = 0.002) and no significant difference in the distribution in NACT modality. Our finding suggests that patients with advanced-stage might have better survival implications when the chemotherapy schedule is optimized. Thus, the risk versus benefit of schedule modification must be carefully managed to ensure optimal chemotherapeutic outcomes while balancing the concurrent toxicity.
{"title":"The Impact of Chemotherapy Schedule Modification on Survival Outcome among Breast Cancer Patients Receiving Adjuvant or Neoadjuvant Treatment Modalities","authors":"Gunasekaran Gobi Hariyanayagam, Sabri Wan Mohd Akmal Bin Wan, Gunasekaran Shargunan Selvanthan, Gunasekaran Sera Selvanthansundram, Selvarajoo Kavisha","doi":"10.23937/2378-3419/1410171","DOIUrl":"https://doi.org/10.23937/2378-3419/1410171","url":null,"abstract":"Chemotherapy schedule has been reported to increase the risk of suboptimal outcomes among cancer patients receiving chemotherapy with variying outcome between treatment modality. This study investigates the Overall Survival (OS) and Hazard of Death (HR) of breast cancer patients with chemotherapy schedule modification stratified against adjuvant (ACT) and neoadjuvant (NACT) treatment modalities. The data required for this study was extracted from hospital based registry. Those patients included in the study were adult female patients receiving chemotherapy between 2013 and 2017 and completed all six chemotherapy cycles. Patients who completed all cycle with a cumulative length of delay < 7 days was categorized as 'no schedule modification' and patients who completed all cycle with the cumulative length of delay ≥ 7 days were categorized as 'with schedule modification'. The Kaplan-Meier estimator was used to estimate survival curves for each covariate and the log rank test was used to evaluate the differences in survival times for each category. Among 124 patients included in the study,93 patients were censoredand 31 events was observed, providing an OS of 75.0% with a mean survival of 54.09 months (95% CI 49.36-58.83). There was significantly higher survival (p < 0.001) in ACT treatment (83.9%) and higher mortality in NACT treatment modalities (51.6%). Among ACT treatment modality, those with no schedule modification had a significant proportion of patients surviving(p = 0.04) compared to patients with schedule modification . The OS was significantly different between age (p = 0.013), stage (p = 0.022) and chemotherapy (p = 0.002) and no significant difference in the distribution in NACT modality. Our finding suggests that patients with advanced-stage might have better survival implications when the chemotherapy schedule is optimized. Thus, the risk versus benefit of schedule modification must be carefully managed to ensure optimal chemotherapeutic outcomes while balancing the concurrent toxicity.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"58 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73268425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-12-31DOI: 10.23937/2378-3419/1410173
Niakan Behzad
It is suggested that a cause of inefficacy in dendritic cell vaccine is dendritic cell dysfunction. It is proposed that dendritic cell dysfunction is possibly due to the immune-regulatory function of activated platelets in cancer patients. It is suggested that activated platelets in cancer patient suppress dendritic cell activity against a malignant growth. A low platelet count prior to the removal of dendritic cells would possibly yield less dysfunctional dendritic cells. If a low platelet count persist until a complete platelet turnover occurs possibly then the dendritic cells may be less dysfunctional. Furthermore, possibly a temporary immune paralysis may allow collecting dendritic cells least manipulated by the cancerous growth.
{"title":"Proposed Experimental Preparation and Administration of Dendritic Cell Vaccine for Treatment of Cancer (Metastatic Castration-Resistant Prostate Cancer)","authors":"Niakan Behzad","doi":"10.23937/2378-3419/1410173","DOIUrl":"https://doi.org/10.23937/2378-3419/1410173","url":null,"abstract":"It is suggested that a cause of inefficacy in dendritic cell vaccine is dendritic cell dysfunction. It is proposed that dendritic cell dysfunction is possibly due to the immune-regulatory function of activated platelets in cancer patients. It is suggested that activated platelets in cancer patient suppress dendritic cell activity against a malignant growth. A low platelet count prior to the removal of dendritic cells would possibly yield less dysfunctional dendritic cells. If a low platelet count persist until a complete platelet turnover occurs possibly then the dendritic cells may be less dysfunctional. Furthermore, possibly a temporary immune paralysis may allow collecting dendritic cells least manipulated by the cancerous growth.","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"60 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"86969297","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2022-06-30DOI: 10.23937/2378-3419/1410169
Devi Aparna, A. Usha, Okaly Geeta V Patil, H. Raghavendra
{"title":"Carcinosarcoma EX Pleomorphic Adenoma of Parotid: An Unusual Entity, A Report of Two Cases with Brief Review of Literature","authors":"Devi Aparna, A. Usha, Okaly Geeta V Patil, H. Raghavendra","doi":"10.23937/2378-3419/1410169","DOIUrl":"https://doi.org/10.23937/2378-3419/1410169","url":null,"abstract":"","PeriodicalId":13873,"journal":{"name":"International journal of cancer and clinical research","volume":"139 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85226153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：